RNA-seq analysis regarding antiandrogen (enzalutamide) effect on gene expression in castration-resistant prostate cancer (CRPC) xenograft model. RNA-seq analysis regarding antiandrogen (enzalutamide) effect on gene expression in castration-resistant prostate cancer (CRPC) xenograft model

VCaP prostate cancer xenografts grown in castrated mice were treated with antiandrogen (enzalutamide), and samples were obtained during treatment response (Enza I: 5 days after initiation of the treatment) and after the treatment resistance had occurred (Enza II: 47 days after initiation of the treatment). Overall design: Rna-seq analysis of Enza I (n = 10) and Enza II (n=10) tumor samples